“Until now, patients living with MCT8 deficiency and their families had no FDA-approved treatment option,” said Marina Zemskova, M.D., Deputy Director of the Division of General Endocrinology in the FDA’s Center for Drug Evaluation and Research.

MCT8 deficiency is a rare genetic disorder that primarily affects males. It results from a faulty gene that provides instructions for making the MCT8 transporter, a critical protein responsible for carrying thyroid hormone into the brain. Without the MCT8 transporter, thyroid hormone cannot cross the blood-brain barrier. As a result, the brain receives too little of the hormone, while excessive levels accumulate in the bloodstream. Patients with MCT8 deficiency can experience debilitating effects, including the inability to walk or sit independently, absent or severely limited speech, intellectual disability, feeding difficulties and chronic stress on the heart and metabolism.

Tiratricol Addresses Elevated Thyroid Hormone Levels

The treatment challenge associated with MCT8 deficiency is linked to the malfunctioning transporter required to deliver thyroid hormone into cells. “The challenge in treating MCT8 deficiency has always been that the protein needed to deliver thyroid hormone into cells is the one that isn’t working,” said Hylton V. Joffe, M.D., MMSc, Director of the Office of Cardiology, Hematology, Endocrinology, and Nephrology in the FDA’s Center for Drug Evaluation and Research.

“This drug sidesteps that problem, as its active ingredient, tiratricol, can enter cells on its own without relying on the broken transporter, leading to a decrease in the elevated blood thyroid hormone levels,” he added.

The effectiveness of Emcitate was assessed through two clinical studies involving patients ranging from infants to adults. These included an international, multi-center, randomized, placebo-controlled trial (NCT05579327) and a longer-term open-label study. Across the two studies, patients receiving Emcitate experienced reductions in excess thyroid hormone levels in the bloodstream, along with improvements in cardiovascular and metabolic symptoms affected by thyroid levels, including systolic blood pressure and heart rate.

Once-Daily Emcitate Treatment

Emcitate is administered once daily as a liquid suspension and can be taken by mouth or through a feeding tube for patients who have difficulty swallowing. This provides an administration option for patients with a wide range of abilities. The most common side effects reported were diarrhea, vomiting, rash and excessive sweating. Patients who are taking another thyroid medication should consult their healthcare provider before beginning Emcitate because the two medications should not be used together. Emcitate received Orphan Drug, Rare Pediatric Disease, Fast Track and Breakthrough Therapy designations, along with Priority Review. The approval of Emcitate was granted to Egetis Therapeutics US Inc.

“The approval of FAYUVI reflects years of research from scientists and developers, as well as unwavering support from so many families and patient organizations in the face of a devastating, universally fatal disease with no treatment options. This is a historic milestone for a community that has waited far too long, but has never given up hope,” said Emil D. Kakkis, M.D., Ph.D., chief executive officer and president of Ultragenyx.

“FDA approval is an important first step toward our long-term goal to bring this treatment option to families of children with Sanfilippo syndrome Type A around the world,” he added.

Community Marks Approval After Decades of Effort

The approval also represents a significant milestone for the Sanfilippo syndrome Type A community, according to Glenn O’Neill, president and co-founder of the Cure Sanfilippo Foundation, and Terri Klein, CNPM, MPA, president and chief executive officer of the National MPS Society.

“The U.S. FDA approval of FAYUVI is a milestone that the Sanfilippo syndrome Type A community spent decades fighting to achieve: the first-ever treatment for a disease that relentlessly steals a child’s abilities, independence, and future,” said O’Neill.

Disease Profile and FAYUVI Treatment

Sanfilippo syndrome Type A is an ultra-rare, fatal lysosomal storage disease that primarily affects the brain and is marked by rapid, progressive neurodegeneration beginning in early childhood. Children generally develop progressive global developmental delay before experiencing the loss of cognitive, language, and motor function, ultimately leading to early death.

The disease is estimated to affect approximately 3,000 to 5,000 patients in commercially accessible geographies, with a median life expectancy of 15 years. Sanfilippo syndrome Type A results from a deficiency of the sulfamidase (SGSH) enzyme, causing heparan sulfate substrate to accumulate in cells and resulting in progressive damage to the central nervous system. FAYUVI is a single-dose intravenous AAV9 gene therapy designed to deliver a functional copy of the deficient enzyme gene that can express and replace the SGSH enzyme.

“This gene therapy addresses a pressing unmet clinical need and offers families a promising therapeutic option,” said Kevin M. Flanigan, M.D., director of the Center for Gene Therapy at Nationwide Children’s Hospital and principal investigator on the study that led to its approval.

Clinical Data Support Standard Full Approval

The development of FAYUVI involved substantial difficulties before the therapy reached final delivery. The Company hopes the approval will revitalize investment in other ultra-rare gene therapies. Haiyan Fu, PhD, and Doug McCarty, PhD, developed the therapy during their tenures at Ohio State University/Nationwide Children’s Hospital, after which it was licensed to Abeona. Despite positive clinical data, funding constraints emerged, prompting Abeona to make the pivotal decision to out-license the asset to Ultragenyx and ensure that the treatment could reach patients. Ultragenyx thanked the researchers, the development and leadership team at Abeona, families, patient advocacy groups, and investigators who worked through the obstacles over the years.

The approval of FAYUVI is supported by data from the pivotal Transpher A trial and long-term follow-up studies. The studies demonstrated clinical benefit relative to the decline observed in natural history, together with a durable treatment effect across clinical assessments and multiple biomarkers while maintaining an acceptable safety profile. Clinical data now extend to up to nearly 8 years of follow-up.

Biochemical efficacy in replacing the missing enzyme was shown through a reduction in accumulated cerebral spinal fluid (CSF) heparan sulfate (HS) levels throughout the study and across all age groups. Clinical efficacy was evaluated using patients’ mean change in Bayley-III Cognitive raw score from 24 to 60 months of age. FAYUVI-treated patients from the modified intention-to-treat (mITT) population (N=17) were compared with untreated patients with Sanfilippo syndrome Type A from an external, comparable natural history cohort (N=27). During the study period, FAYUVI-treated patients (mITT) demonstrated a 23.5 point higher (p<0.0001) cognitive score over natural history, providing the efficacy basis for standard full approval.

ESR1 mutations are resistance mutations that tumors may acquire while a patient is receiving an aromatase inhibitor, a type of endocrine therapy commonly used as a front-line treatment for locally advanced or metastatic breast cancer. At the time HR-positive metastatic breast cancer is diagnosed, fewer than 5 percent of patients have this tumor mutation. Following disease progression while receiving an aromatase inhibitor, however, nearly 40 percent of patients will have the mutation.

“Women living with metastatic breast cancer face an uphill battle as their tumors continuously evolve to escape treatment. We owe them every weapon in our arsenal.” said Acting FDA Commissioner Kyle Diamantas, J.D.

“Today’s approval delivers a win to these patients by granting them a targeted therapy designed specifically to overcome resistance, giving them more time before their disease progresses,” he added.

Accelerated Approval Requires Confirmatory Evidence

Etcamah received accelerated approval based on progression-free survival, measuring how long patients remained without worsening disease from the point at which the resistance mutation was first identified in the blood. The FDA’s accelerated approval program permits earlier authorization of medicines intended for serious conditions that address an unmet medical need when approval is supported by surrogate or intermediate endpoints. Because it remains uncertain whether treating patients at the point of resistance mutation detection, instead of waiting for confirmed disease progression, provides a clinically meaningful benefit, the FDA has required confirmatory studies to establish and further describe the clinical benefit.

“I commend both the FDA and the sponsor for their commitment to advancing cancer care and securing this accelerated approval,” said Angelo de Claro, M.D., director of the FDA’s Oncology Center of Excellence.

ctDNA consists of small pieces of tumor DNA that are released into the bloodstream, providing an opportunity to detect resistance mutations at an earlier molecular stage. To support the identification of appropriate patients with breast cancer, the FDA also authorized the Guardant360 CDx assay as a companion diagnostic device for identifying patients with ESR1 mutations who may receive camizestrant.

Clinical Trial Shows Longer Progression-Free Survival

The efficacy of Etcamah was assessed in a clinical trial comparing a switch to the oral tablet in combination with a CDK4/6 inhibitor against continued treatment with an aromatase inhibitor alongside a CDK4/6 inhibitor. The estimated median progression-free survival reached 16 months among patients receiving Etcamah and a CDK4/6 inhibitor. By comparison, the estimated median progression-free survival was 9.2 months in the aromatase inhibitor and CDK4/6 inhibitor arm. The results form the clinical basis for the expanded breast cancer treatment option under the FDA’s accelerated approval pathway.

“For patients with Alexander disease and their families, there have been no approved treatment options — only supportive care while the disease progresses,” said Emily Freilich, M.D., Director of the Division of Neurology I in the FDA’s Center for Drug Evaluation and Research.

“Today’s approval is a landmark moment for this community, offering the first therapy that addresses the underlying cause of this rare and serious disease,” she added.

Alexander disease is a rare and progressive neurological disorder linked to mutations in the gene responsible for producing glial fibrillary acidic protein (GFAP). When the protein is abnormal, it builds up in the brain’s supportive cells and progressively damages the nervous system. The disease affects less than 1 in a million people and can result in serious, potentially life-threatening complications, including seizures, loss of developmental milestones, difficulty walking, muscle weakness, and increased pressure in the brain.

Zanvastro Targets Abnormal GFAP Protein

Zanvastro belongs to a class of medicines known as antisense oligonucleotides. The treatment works by reducing the production of abnormal GFAP protein before it has the opportunity to accumulate and cause additional damage. The medicine is administered through an injection into the spinal canal once every three months, with the procedure performed by a trained healthcare professional.

The safety and efficacy of Zanvastro were assessed through a multicenter, randomized, controlled clinical study (NCT04849741), which enrolled 49 pediatric and adult patients with Alexander disease who were 2 years of age and older. The evaluation also included an open-label substudy involving 4 patients less than 2 years of age. Given the rarity of Alexander disease and the broad age range across which it can occur, the FDA considered the available evidence to support an indication extending from infancy through adulthood.

Clinical Study Shows Improvement in Motor Function

Among patients aged 5 years and older who had measurable walking difficulties at baseline, those receiving Zanvastro demonstrated significantly better walking speed at 61 weeks than patients who received no treatment. For children aged 2 to 4 years, walking speed was not considered a reliable way to measure progress. Instead, researchers used a broader assessment of motor skills covering standing, walking, running, and jumping. Children receiving Zanvastro improved on this assessment, while children in the control group declined.

For patients under 2 years of age, direct clinical trial evidence was limited because of the rarity of the disease and the absence of a concurrent control group. Pharmacokinetic modeling indicated that drug levels among patients in this age group were expected to be similar to those observed in older children receiving the same dose. The finding was further supported by safety information from four patients under 2 years of age who were treated in the study, along with safety data from older pediatric patients. This evidence supported extending the indication to the youngest patients while maintaining the evidentiary standards required for approval.

Safety Profile and FDA Designations

The most common side effects associated with Zanvastro include vomiting, back pain, cough, headache, and post-lumbar puncture syndrome. Patients and caregivers have been advised to notify their healthcare provider if symptoms consistent with meningitis occur, as aseptic meningitis has been reported among patients treated with Zanvastro. Patients and healthcare providers should carefully review the full prescribing information when considering treatment decisions.

Zanvastro received Orphan Drug, Fast Track, Breakthrough Therapy, and Rare Pediatric Disease and Priority Review Voucher designations. These designations reflect the serious and rare nature of Alexander disease and FDA’s commitment to rare disease drug development. The approval of Zanvastro for the treatment of Alexander disease was granted to Ionis Pharmaceuticals, Inc.

Mimrylo provides a new treatment approach for patients whose polycythemia vera has not been adequately controlled through existing therapies. The medicine is the first approved treatment for polycythemia vera designed to mimic hepcidin, a hormone that naturally regulates iron in the body. By restricting the amount of iron available for producing new red blood cells, Mimrylo is intended to reduce their overproduction and help maintain red blood cell levels under control. The treatment therefore gives patients whose disease remains inadequately controlled with existing therapies another option.

“People living with polycythemia vera have long faced the challenge of managing a chronic blood disorder with frequent blood draws to help address the consequences of the red blood cell overproduction,” said Tanya Wroblewski, M.D., Director of the Division of Nonmalignant Hematology within the FDA’s Center for Drug Evaluation and Research.

“Today’s approval of Mimrylo offers a new, first-in-class option that has the potential to meaningfully reduce patient burden,” she added.

A central objective in treating polycythemia vera is maintaining the proportion of red blood cells in the blood, known as hematocrit, below 45% in order to lower cardiovascular risks. Phlebotomy is frequently used to achieve this goal. The procedure removes blood from a vein to reduce the number of red blood cells in the body. For some patients, however, treatment does not prevent the need for repeated phlebotomies, leaving them with an ongoing treatment burden associated with the rare blood disorder.

VERIFY Trial Evaluates Safety and Efficacy

Phase 3 Study Shows Reduced Need for Phlebotomy

The safety and efficacy of Mimrylo were assessed through the VERIFY trial, a multicenter, randomized, double-blind, placebo-controlled phase 3 study involving 293 adults with polycythemia vera. Participants in the trial required frequent phlebotomies despite continuing standard-of-care therapy. They were randomized 1:1 to receive either Mimrylo or placebo over a 32-week period. Treatment with Mimrylo began at 19 mg and was administered subcutaneously (under the skin) once weekly. The dose was then titrated with the objective of maintaining hematocrit levels below 45%.

The trial measured efficacy according to the proportion of patients who did not meet the criteria for phlebotomy between weeks 20 and 32 of the study. During the 32-week period, 76.9% of patients receiving Mimrylo did not require any phlebotomies, compared with 32.9% of patients who received placebo. The most common adverse reactions reported with Mimrylo were injection site reactions and anemia.

Mimrylo received priority review, with the approval granted to Takeda Pharmaceuticals America, Inc.

Rasonque is administered as a tablet once daily and works by targeting multiple forms of a protein called RAS. The protein is a key driver of tumor growth in most patients with pancreatic adenocarcinoma, a cancer that develops from cells lining the ducts of the pancreas. The approval covers adults with metastatic pancreatic cancer in the form of pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

“Today’s approval provides a critical new option for patients facing an extraordinarily difficult and historically hard-to-treat cancer. It is our fundamental duty to deliver more cures and meaningful treatments to patients as quickly as possible,” said Acting FDA Commissioner Kyle Diamantas, J.D.

“I am immensely proud of the dedicated FDA scientists whose fast, thorough review and relentless commitment made this groundbreaking milestone a reality,” he added.

Clinical Trial Shows Survival Benefit

Pancreatic adenocarcinoma represents approximately 90% to 95% of the 67,000 new cases of pancreatic cancer diagnosed in the United States each year, according to the National Cancer Institute. Although pancreatic adenocarcinoma makes up roughly 3.2% of all cancer diagnoses, it contributes a disproportionately high share of cancer deaths. The source attributes that burden to the disease’s typically late detection, aggressive course and historically limited treatment options.

Evidence supporting Rasonque came from a randomized, open-label, multicenter clinical trial involving 500 adults with previously treated metastatic pancreatic adenocarcinoma. In the study, Rasonque increased median overall survival to 13.2 months, compared with 6.7 months for standard chemotherapy.

“This drug showed unprecedented results in an area of high unmet need,” said Angelo de Claro, M.D., director of the FDA’s Oncology Center of Excellence.

“The approval was granted 6.5 months before the user fee deadline, demonstrating the FDA’s commitment to accelerating the approval of new cancer treatments for patients with serious and life-threatening conditions,” he added.

Rasonque Receives Multiple FDA Designations

The FDA granted Rasonque Breakthrough Therapy and Orphan Drug designations, while the treatment also received Priority Review for this indication. The application underwent an additional review through the Commissioner’s National Priority Voucher pilot program, which is intended to accelerate the review of therapies addressing national public health priorities.

In May 2026, the FDA issued a “safe to proceed” letter allowing the sponsor to begin an expanded access treatment protocol for Rasonque. This enabled patient access to the investigational drug before approval under applicable FDA regulations.

A 64-week, late-stage study demonstrated that participants who took 25 mg of oral semaglutide once a day went on to lose an average of 16.6% of their body weight, as compared with 2.7% for those on a placebo. The pill was given a nod for chronic weight management within adults with obesity or overweight and a minimum of one related health condition, therefore widening the potential patient pool at a time when the insurers, employers, and governments are battling it out with spiraling healthcare expenses related to obesity. It could also help open the door to tens of millions of untapped patients in an international market, forecast to be somewhere around $150 billion a year by the next decade. As per chief AI officer Anand Iyer at Welldoc, a telehealth firm, there is going to be a huge uptake in the patient base that is about to be seen as new indications open up and as the oral versions hit the market. Novo’s executive vice president of U.S. operations, David Moore, said that a daily pill could also boost the interest and uptake of the drug. Novo is apparently manufacturing the pill in the United States in North Carolina and has been building up supplies of the pill for quite some time now to ensure that it has enough supply.

Around 40% of American adults are obese, as per the U.S. government data, and almost 12% say that they are at present on GLP-1 drugs, as per a poll published in November 2025 by KFF, the health policy research organization. Novo apparently had a first-to-market advantage in terms of injectables; however, it initially struggled to meet that explosive demand. Eventually, Lilly went ahead with its Zepbound, which now goes on to lead when it comes to weekly U.S. prescriptions. Novo, along with analysts, says that a weight-loss pill would very well address the injection hesitancy and hence lead to expansion in access.

According to managing director and partner at BCG, Christopher Chrisman, the pills are not going to displace or replace the injections, adding that some patients may prefer to go ahead with their weekly injections. However, the pills do offer clear benefits to some people. There is indeed a level of travel convenience and no requirement to have a fridge,” he added. Novo remarked that the 1.5-milligram starting dose of the Wegovy pill is going to be available in early January 2026. Novo as well as Lilly had gone on to agree to provide starter doses in terms of their weight-loss pills at $149 for every month for the U.S. government Medicare and Medicaid health insurance programs and also to cash-paying customers through the direct-to-consumer TrumpRx site from the White House.

Novo recently slashed the cash price for Wegovy to $349 per month, from $499. Mike Doustdar, the Novo CEO, said that in November 2025, people making use of the weight-loss drugs showed more consumer-like behavior as compared to its traditional diabetes patients, therefore acknowledging that the company is required to adapt to this and also bring in the new expertise. Whether another semaglutide product can go ahead and solve the current ills of Novo remains to be seen. The weight loss pill from Novo Nordisk, oral semaglutide, has to be taken in the morning on an empty stomach, which is 30 minutes prior to eating, drinking, or using any kind of other oral medication.

According to the Chief Medical Officer and Head of Global Product Development at Roche, Levi Garraway, MD, PhD, since follicular lymphoma often needs lifelong management, decreasing the burden of care for such individuals is indeed of major importance. Due to this FDA approval, treatment can now be administered in about one minute, which prominently decreases the time patients spend within the clinic and helps to sync care along with their individual requirements as well as preferences.

It is well to be noted that VELO decreases the treatment administration time with an approx. one-minute injection as compared with a 2-4 hour intravenous (IV) infusion. Like Lunsumio, which is administered intravenously, Lunsumio VELO by Roche can be administered outpatient and is a fixed-duration treatment that is given for a defined period, and that could be as short as six months. By contrast, treat-to-progression treatment alternatives are designed to be given to patients indefinitely until the time of disease progression or till treatment can no longer be tolerated. Tennessee Oncology and One Oncology’s Dr. Ian Flinn, MD, PhD, says that this approval is a major step when it comes to broadening access to effective treatments for people who are living with follicular lymphoma. Due to its manageable cytokine release syndrome profile as well as decreased administration time, Lunsumio VELO helps oncologists to roll out advanced care across the community practice settings.

Interestingly, the FDA approval has received support from the primary analysis of the GO29781 study, which evaluated Lunsumio VELO across patients having third-line or later (3L+ FL). Inferences showed that the objective response rate as well as the complete response rate within patients treated with Lunsumio VELO were 75% (95% confidence interval [CI]: 64–83%) and 59% (95% CI: 48–69%), respectively. The median duration when it comes to response was 22.4 months – 95% CI: 16.8–22.8. The most common adverse reactions (≥20%) were the injection site reactions, such as fatigue, rash, cytokine release syndrome (CRS), COVID-19 infection, and musculoskeletal pain, as well as diarrhea. Notably, the CRS rate was 30%, and events were mostly low grade, i.e., Grade 1–2 (28%) and Grade 3 (2.1%) occurred in Cycle 1, and all resolved post a median duration of two days (range: 1–15). Apparently, CRS can be severe as well as life-threatening.

It is well to be noted that Lunsumio IV was the first bispecific antibody that was approved for 3L+ FL. Long-term data from the SC as well as IV arms of the GO29781 study were presented at the 67th American Society of Hematology Annual Meeting and Exposition. These data have been submitted to other healthcare authorities throughout the world. Recently, the European Commission went on to grant a conditional marketing authorization of Lunsumio SC when it comes to the treatment of adult patients having R/R FL post two or more lines of systemic therapy.

Roche goes on to advance its bispecific antibody programme within the gamut of lymphoma, with ongoing phase III studies assessing Lunsumio and Lunsumio VELO within the earlier lines of treatment. This goes on to include the SUNMO study, which investigates the Lunsumio VELO in combination with Polivy® (polatuzumab vedotin) in the second-line or later large B-cell lymphoma, as well as the MorningLyte study, which investigates the Lunsumio VELO in combination with lenalidomide in past untreated FL.

The Cytokinetics Myqorzo approval follows a period of volatility for the biotech, which was founded in 1997 and has only now brought its first product to market. The company faced setbacks when a late-stage ALS program failed and another cardiovascular therapy was rejected by regulators, but Myqorzo’s progress reshaped its development outlook.  Like Camzyos, Myqorzo is a cardiac myosin inhibitor that works by relaxing heart muscle contraction to improve cardiac function, and both drugs are approved for the obstructive form of hypertrophic cardiomyopathy. But differences in how the therapies are prescribed could influence how the market develops. Myqorzo carries a heart failure warning similar to Camzyos, while its risk mitigation requirements are less restrictive. RBC Capital Markets analyst Leonid Timashev wrote that Myqorzo’s protocol allows more flexible dose adjustments, less frequent echocardiograms, and minimal drug-interaction monitoring, factors he said “should materially lower barriers to prescribing” compared with Camzyos.

Despite the significance of the Cytokinetics Myqorzo approval, investor reaction was muted, with analysts noting that labeling outcomes largely matched expectations. Stifel analyst James Condulis said there remains “debate” around the “extent” of Myqorzo’s differentiation from Camzyos, even as attention turns to upcoming clinical data. Cytokinetics is expected to report results from a study evaluating Myqorzo in patients with the non-obstructive form of hypertrophic cardiomyopathy, a setting in which Camzyos failed in a Phase 3 trial. Some analysts believe Myqorzo’s broader therapeutic dosing range could offer an advantage, though outcomes remain to be seen. “We’re bullish and expect [Myqorzo] to become the best [and] only drug for the entire HCM spectrum,” Condulis wrote.

Pricing for Myqorzo is expected to be “in line with” Camzyos, according to a company spokesperson, with details to be disclosed ahead of launch. Camzyos entered the market with an annual wholesale acquisition cost of $89,500. Myqorzo has also received regulatory clearance in China, extending its geographic footprint beyond the U.S. market. As Cytokinetics transitions from a development-stage biotech to a commercial drug company, the Cytokinetics Myqorzo FDA approval represents a pivotal step in establishing a long-term presence in cardiovascular therapeutics.

Following the initial dosing phase, patients receive inebilizumab-cdon twice yearly, a schedule designed to simplify long-term management for individuals who may find frequent or complex regimens difficult to maintain. In addition to its newly approved indication for generalized myasthenia gravis, the therapy is also approved for adult patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder and immunoglobulin G4-related disease. Commenting on the decision, Jay Bradner, MD, executive vice president of research and development at Amgen, said in a news release, “This approval marks a significant advancement for people living with gMG. By selectively targeting CD19-positive B cells, [inebilizumab] offers a new approach to treatment that addresses a biological root cause of disease. [Inebilizumab] is conveniently dosed twice a year and delivers durable efficacy, helping people manage debilitating symptoms that can compromise daily function—including trouble breathing, speaking, and seeing.”

The FDA decision on inebilizumab-cdon for generalized myasthenia gravis was supported by findings from MINT (NCT04524273), a randomized, double-blind, placebo-controlled, parallel-group phase 3 trial evaluating efficacy and safety in adults with gMG. The study enrolled 238 patients, including 190 who were AChR-positive and 48 who were MuSK-positive. Participants were randomized to receive intravenous inebilizumab at a dose of 300 mg on days 1 and 15, with an additional dose on day 183 for AChR-positive patients, or a matching placebo. Treatment continued for 52 weeks in AChR-positive participants and 26 weeks in MuSK-positive participants. The primary endpoint assessed change from baseline in the Myasthenia Gravis Activities of Daily Living score at week 26, while a key secondary endpoint measured change in the Quantitative Myasthenia Gravis score over the same period.

Results from the trial showed that patients treated with inebilizumab achieved greater reductions in disease activity than those receiving placebo, supporting the decision as the FDA approves inebilizumab-cdon for generalized myasthenia gravis. Least-squares mean changes in MG-ADL scores were –4.2 with inebilizumab compared with –2.2 for placebo, while QMG scores declined by –4.8 versus –2.3, respectively. Richard J. Nowak, MD, MS, global principal investigator and director of the Myasthenia Gravis Clinic at Yale University, said in the news release, “[Inebilizumab] showed strong efficacy at 26 weeks in both AChR-positive and MuSK+ patients, with AChR+ patients continuing to improve through 52 weeks in MINT.” The most commonly reported adverse events included headache, cough, nasopharyngitis, infusion-related reactions, and urinary tract infections, with no higher incidence of serious adverse events observed. Manufacturers noted the potential risk of infections and possible fetal harm. Responding to the approval, Samantha Masterson, president and CEO of the Myasthenia Gravis Foundation of America, said the therapy offers durable efficacy and extended treatment-free intervals for people living with gMG.